JP2024520205A5 - - Google Patents

Info

Publication number
JP2024520205A5
JP2024520205A5 JP2023571857A JP2023571857A JP2024520205A5 JP 2024520205 A5 JP2024520205 A5 JP 2024520205A5 JP 2023571857 A JP2023571857 A JP 2023571857A JP 2023571857 A JP2023571857 A JP 2023571857A JP 2024520205 A5 JP2024520205 A5 JP 2024520205A5
Authority
JP
Japan
Application number
JP2023571857A
Other languages
Japanese (ja)
Other versions
JP2024520205A (ja
JPWO2022246251A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/030335 external-priority patent/WO2022246251A2/en
Publication of JP2024520205A publication Critical patent/JP2024520205A/ja
Publication of JP2024520205A5 publication Critical patent/JP2024520205A5/ja
Publication of JPWO2022246251A5 publication Critical patent/JPWO2022246251A5/ja
Pending legal-status Critical Current

Links

JP2023571857A 2021-05-21 2022-05-20 Unc13aの発現を調節するための化合物 Pending JP2024520205A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163191905P 2021-05-21 2021-05-21
US63/191,905 2021-05-21
PCT/US2022/030335 WO2022246251A2 (en) 2021-05-21 2022-05-20 Compounds for modulating unc13a expression

Publications (3)

Publication Number Publication Date
JP2024520205A JP2024520205A (ja) 2024-05-22
JP2024520205A5 true JP2024520205A5 (https=) 2025-05-26
JPWO2022246251A5 JPWO2022246251A5 (https=) 2025-05-26

Family

ID=84140868

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571857A Pending JP2024520205A (ja) 2021-05-21 2022-05-20 Unc13aの発現を調節するための化合物

Country Status (4)

Country Link
US (1) US20240301415A1 (https=)
EP (1) EP4341406A4 (https=)
JP (1) JP2024520205A (https=)
WO (1) WO2022246251A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2603454A (en) 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
CA3227115A1 (en) * 2021-07-21 2023-01-26 Wen-Hsuan Chang Unc13a antisense oligonucleotides
GB202117758D0 (en) * 2021-12-09 2022-01-26 Ucl Business Ltd Therapeutics for the treatment of neurodegenerative disorders
CN118974254A (zh) * 2021-12-21 2024-11-15 豪夫迈·罗氏有限公司 靶向unc13a的反义寡核苷酸
AU2023356317A1 (en) * 2022-10-05 2025-05-15 Trace Neuroscience, Inc. Unc13a antisense oligonucleotides and uses thereof
WO2024178223A1 (en) * 2023-02-24 2024-08-29 Northwestern University Antisense oligonucleotides for preventing unc13a misplicing
WO2024220746A2 (en) 2023-04-21 2024-10-24 Flagship Pioneering Innovations Vii, Llc Rnai agents targeting fatty acid synthase and related methods
AU2024299328A1 (en) 2023-07-21 2026-01-22 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
US20250263702A1 (en) 2024-02-19 2025-08-21 Flagship Pioneering Innovations Vii, Llc Rnai agents targeting cideb and related methods
WO2025217275A2 (en) 2024-04-10 2025-10-16 Flagship Pioneering Innovations Vii, Llc Immune cell targeted compositions and related methods
WO2026080323A1 (en) * 2024-10-09 2026-04-16 Quralis Corporation Treatment of neurological diseases using modulators of unc13a gene transcripts

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1123038A (zh) * 1993-05-11 1996-05-22 北卡罗来纳大学查珀尔希尔分校 阻止异常剪接的反义寡核苷酸及其使用方法
US20060008800A1 (en) * 2001-11-05 2006-01-12 Christian Rosenmund Unc-13 in the modulation of neurotransmission and secretion events
EP2305812A3 (en) * 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
EP1752536A4 (en) * 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
US20110195848A1 (en) * 2010-01-08 2011-08-11 Roopra Avtar S Gene expression and breast cancer
US10517889B2 (en) * 2017-09-08 2019-12-31 Ionis Pharmaceuticals, Inc. Modulators of SMAD7 expression
GB2603454A (en) * 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders

Similar Documents

Publication Publication Date Title
JP2024520205A5 (https=)
JP2025500335A5 (https=)
BR102022025291A2 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
CN307046367S (https=)
BY13163U (https=)
BY13176U (https=)
BY13174U (https=)
BY13172U (https=)
BY13170U (https=)
BY13169U (https=)